Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 5, Issue 3, Pages e1098-e1098
Publisher
Springer Nature
Online
2014-03-06
DOI
10.1038/cddis.2014.61
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
- (2014) G. L. Kelly et al. GENES & DEVELOPMENT
- Getting away with murder: how does the BCL-2 family of proteins kill with immunity?
- (2013) Thibaud T. Renault et al. Annals of the New York Academy of Sciences
- ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
- (2013) C. J. Vandenberg et al. BLOOD
- Pro-Apoptotic Protein Noxa Regulates Memory T Cell Population Size and Protects against Lethal Immunopathology
- (2013) F. M. Wensveen et al. JOURNAL OF IMMUNOLOGY
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
- Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killing
- (2013) Kerstin Brinkmann et al. LEUKEMIA & LYMPHOMA
- Mcl-1 is essential for the survival of plasma cells
- (2013) Victor Peperzak et al. NATURE IMMUNOLOGY
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Ubiquitin C-Terminal Hydrolase-L1 Potentiates Cancer Chemosensitivity by Stabilizing NOXA
- (2013) Kerstin Brinkmann et al. Cell Reports
- Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia
- (2012) D. Buet et al. BLOOD
- Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice
- (2012) E. Ottina et al. BLOOD
- Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma
- (2012) Y. Oki et al. BLOOD
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- The BH3-Only Proteins Bim and Puma Cooperate to Impose Deletional Tolerance of Organ-Specific Antigens
- (2012) Daniel H.D. Gray et al. IMMUNITY
- Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
- (2012) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma
- (2012) S-S Wenzel et al. LEUKEMIA
- Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
- (2011) G. Sonpavde et al. ANNALS OF ONCOLOGY
- BH3-only protein Noxa regulates apoptosis in activated B cells and controls high-affinity antibody formation
- (2011) F. M. Wensveen et al. BLOOD
- Reduced mast cell and basophil numbers and function in Cpa3-Cre; Mcl-1fl/fl mice
- (2011) J. N. Lilla et al. BLOOD
- Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice
- (2011) P. N. Kelly et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Genetically defining the mechanism of Puma- and Bim-induced apoptosis
- (2011) S P Garrison et al. CELL DEATH AND DIFFERENTIATION
- Molecular analysis of neutrophil spontaneous apoptosis reveals a strong role for the pro-apoptotic BH3-only protein Noxa
- (2011) S Kirschnek et al. CELL DEATH AND DIFFERENTIATION
- The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors
- (2011) Ádám Jóna et al. EXPERIMENTAL HEMATOLOGY
- Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia
- (2011) Pooja P Advani et al. Expert Opinion on Drug Metabolism & Toxicology
- Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
- (2011) Neal Ready et al. Journal of Thoracic Oncology
- A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer
- (2011) Maria Q. Baggstrom et al. Journal of Thoracic Oncology
- Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin’s lymphoma cells
- (2010) Zhi-Ming Li et al. CANCER BIOLOGY & THERAPY
- The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
- (2010) Scott Ackler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma
- (2010) J. J. Hwang et al. CLINICAL CANCER RESEARCH
- Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis
- (2010) Sameer A. Parikh et al. Clinical Lymphoma Myeloma & Leukemia
- Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance
- (2010) Laura Bonapace et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
- (2010) Rebecca Suk Heist et al. Journal of Thoracic Oncology
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- Mcl-1 Is Essential for Germinal Center Formation and B Cell Memory
- (2010) I. Vikstrom et al. SCIENCE
- Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
- (2009) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis
- (2009) E M Michalak et al. CELL DEATH AND DIFFERENTIATION
- An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
- (2009) G. Liu et al. CLINICAL CANCER RESEARCH
- 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
- (2009) Susan O'Brien et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma
- (2009) Asher A. Chanan-Khan et al. LEUKEMIA & LYMPHOMA
- Bim and Bmf in tissue homeostasis and malignant disease
- (2009) J D Piñon et al. ONCOGENE
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
- (2008) S. M. O'Brien et al. BLOOD
- AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance
- (2008) K. Balakrishnan et al. BLOOD
- Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
- (2008) Barbara Pro et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax)
- (2008) M. Konopleva et al. CANCER RESEARCH
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
- (2008) A. D. Schimmer et al. CLINICAL CANCER RESEARCH
- Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis
- (2008) S. P. Garrison et al. MOLECULAR AND CELLULAR BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started